Sexual arousal disorder


Also found in: Wikipedia.

Sexual arousal disorder

The inhibition of the general arousal aspect of sexual response.
Mentioned in: Sexual Dysfunction
References in periodicals archive ?
Dare Bioscience announced that it has met the funding requirement for obtaining an exclusive worldwide license to advance SST-6007, a potential treatment for Female Sexual Arousal Disorder, or FSAD.
M2 PHARMA-September 22, 2017-Innovus Partner Luminarie Receives New Zealand Approval for Zestra for Female Sexual Arousal Disorder as a Medical Device I
The women had to score lower than 26 on the Female Sexual Function Index (FSFI) and lower than 11 on the Female Sexual Distress Scale (FSDS) and demonstrate one more of the following female sexual dysfunction (FSD) issues: hypoactive sexual desire disorder (HSDD), female sexual arousal disorder (FSAD), female orgasmic disorder (FOD), or combined genital and subjective arousal disorder.
Efficacy and safety of sildenafil citrate in women with sexual dysfunction associated with female sexual arousal disorder.
Female sexual arousal disorder (FASD) is the recurrent inability to attain sexual activity, or maintain it till completion, e.
The study included 50 women diagnosed with female sexual dysfunction, which included hypoactive sexual desire disorder, female sexual arousal disorder, female orgasmic disorder, or combined genital and subjective arousal disorder.
Instead, it lists female sexual interest/ arousal disorder [FSIAD], which "combines features of HSDD and another condition from the DSM-IV known as female sexual arousal disorder," the FDA pointed out.
Effect of sildenafil on subjective and physiologic parameters of the female sexual response in women with sexual arousal disorder.
Most recently, a pharmacotherapy trial investigated the use of oral sildenafil for the treatment of female sexual arousal disorder as a result of spinal cord injury in a sample of 52 women (North America n=23, Europe n=23, Australia n=4, South Africa n=2).
If the transaction becomes successful, Easton Pharmaceuticals' acquisition will bring the company into the $426-bn a year cosmetics industry to complement its therapeutic line of products including its main product, 'VIORRA', which is a product to treat female sexual arousal disorder.
Another type of sexual arousal disorder has the opposite effect.
Flibanserin, a postsynaptic 5-HT(1A) agonist/5HT(2A) antagonist, has been studied in more than 10,000 women and shown to increase libido and response in those with female sexual arousal disorder (FSAD) and hypoactive sexual desire disorder (HSDD).

Full browser ?